Previous Next

ARCHIVE

№2' 2017

CARDIOLOGY

International Medical Journal, Vol. 23., Iss. 2, 2017, P. 19−23.

HYPERTENSION DEGREE AND FREQUENCY OF ADMINISTRATION OF CERTAIN GROUPS OF CARDIAC DRUGS IN PATIENTS AT THE ANNUAL FOLLOW-UP STAGE OF PACE-MAKER IMPLANTATION

V. N. Karazin Kharkiv National University
V. T. Zaytsev Institute of General and Urgent Surgery of National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine

At present permanent endocardial pacemaking and cardiac resynchronization therapy are recognized and effective methods of treatment of severe rhythm and conduction disorders, as well as chronic heart failure resistant to medication therapy. Pacemaking significantly improves the quality of life and reduces the death rate of the patients. Arterial hypertension is the most common comorbid pathology in patients with implanted pacemakers. Despite the fact that pacemaker implantation normalizes ventricular pump function and improves the quality of life of patients, it can cause blood pressure instability and progression of hypertension. This investigation evaluated the frequency of administration of major groups of cardiac drugs in patients with pacemakers at the annual stage of observation, depending on the degree of hypertension. The results showed that at the annual stage of pacing in patients with arterial hypertension, the frequency of administration of beta−adrenoblockers, Ca antagonists, ACE inhibitors, angiotensin II receptor blockers, antiarrhythmic drugs and inhibitors of HMG CoA reductase increased. The frequency of administration increased due to the increase in arterial hypertension degree. The patients with implanted pacemakers require individualized medication approach, taking into account the degree of arterial hypertension, in particular, strengthening anti−ischemic, anti−hypertensive and anti−arrhythmic therapy.

Key words: pacing, hypertension, drug therapy, annual follow−up period.